NEW
YORK, June 10, 2024 /PRNewswire/ -- The global
protein therapeutics market size is estimated to grow by
USD 172.8 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 9.47% during the forecast period. Increased demand
for mabs is driving market growth, with a trend
towards continued focus on improvement of protein
therapeutics. However, complexities in manufacturing, storage
conditions, distribution policies, and high cost poses a
challenge. Key market players include AbbVie Inc., Amgen Inc.,
AstraZeneca Plc, Biocon Ltd., Biogen Inc., Bristol Myers Squibb
Co., Celltrion Healthcare Co. Ltd., Creative Biolabs, Eli Lilly and
Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., Ipsen
Pharma, Johnson and Johnson Services Inc., LGM Pharma LLC, Midas
Pharma GmbH, Novartis AG, Novo Nordisk AS, Pfizer Inc., PV Pharma
Healthcare Pvt. Ltd., and Sanofi SA.
![Technavio has announced its latest market research report titled Global protein therapeutics market 2024-2028 Technavio has announced its latest market research report titled Global protein therapeutics market 2024-2028](https://mma.prnewswire.com/media/2433352/Global_protein_therapeutics_market_Infographic.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Protein Therapeutics
Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
9.47%
|
Market growth
2024-2028
|
USD 172.8
billion
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
8.44
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
36%
|
Key
countries
|
US, Canada, Germany,
UK, and China
|
Key companies
profiled
|
AbbVie Inc., Amgen
Inc., AstraZeneca Plc, Biocon Ltd., Biogen Inc., Bristol Myers
Squibb Co., Celltrion Healthcare Co. Ltd., Creative Biolabs, Eli
Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals
Ltd., Ipsen Pharma, Johnson and Johnson Services Inc., LGM Pharma
LLC, Midas Pharma GmbH, Novartis AG, Novo Nordisk AS, Pfizer Inc.,
PV Pharma Healthcare Pvt. Ltd., and Sanofi SA
|
Market Driver
In the Protein Therapeutics Market, companies are enhancing
their product offerings to stay competitive. They are focusing on
patients' needs to improve features for enhanced comfort. For
example, LINET and LINAK introduce beds with unique features like
four-section profiles and ultra-low beds. Four-section profiles
offer better sitting positions with less compression, while
ultra-low beds provide safer entry/exit heights. Additionally,
manufacturers like Invacare extend maintenance schedules to reduce
end-users' maintenance costs and increase sales. This product
improvement trend is expected to boost the growth of the Protein
Therapeutics Market.
The Protein Therapeutics market is experiencing significant
growth due to the increasing demand for effective treatments. Lumos
Therapeutics and other key players are developing new proteins and
technologies to treat various diseases. These proteins are used in
therapies for a range of conditions, including chronic diseases and
genetic disorders. Protochetics and Protemeics are important
techniques used in the production of these proteins.
The use of delivery systems, such as peptides and proteins, is
also a trend in this market. Genetically engineered proteins are
also gaining popularity due to their ability to target specific
diseases. The market for these therapies is expected to continue
growing as research and development efforts yield new
treatments.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The protein therapeutics market involves the production of
complex proteins from living organisms, which is a time-consuming
and costly process. This includes steps like fermentation,
clarification, separation, purification, and formulation. Insulin,
a protein, is produced through similar processes, requiring large
investments in biotechnology and sterile facilities.
- Proper storage conditions are crucial to maintain product
efficacy and increase costs. High development costs, complex
manufacturing processes, and sterile conditions contribute to the
high prices of protein therapeutics, posing challenges for
end-users and insurers. Key products include LUCENTIS, Avastin,
HUMIRA, and hemophilia A therapies, with costs ranging from
USD1,800 to USD2,400 per month or USD2,000 per dose.
- The Protein Therapeutics Market faces several challenges in its
growth. One significant challenge is the high cost of production.
The complex process of producing proteins makes it expensive.
Another challenge is the short half-life of many protein
therapeutics, requiring frequent dosing and increasing treatment
costs.
- Additionally, the development of biosimilars and generic
versions of protein therapeutics is intensifying competition in the
market. Furthermore, regulatory requirements for approval and
stringent quality control measures add to the costs and complexity
of bringing new protein therapeutics to market. Lastly, the need
for personalized medicine and the development of new delivery
systems present opportunities but also add to the challenges in the
Protein Therapeutics Market.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
- Product
- 1.1 mAbs
- 1.2 Human insulin
- 1.3 Erythropoeitin
- 1.4 Clotting factors
- 1.5 Others
- Application
- 2.1 Metabolic disorders
- 2.2 Immunologic disorders
- 2.3 Hematological disorders
- 2.4 Cancer
- 2.5 Genetic disorders
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 mAbs- Protein therapeutics market is
experiencing significant growth due to increasing demand for
effective treatments in various therapeutic areas. Biotechnology
companies are investing heavily in research and development to
bring new protein-based therapies to market. These therapies offer
advantages such as high specificity, improved efficacy, and reduced
side effects compared to traditional small molecule drugs. Protein
therapeutics are used in treatments for conditions like cancer,
neurological disorders, and inherited diseases. The market is
expected to continue expanding as new applications and indications
are discovered.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2017-2021) - Download a Sample Report
Research Analysis
The Protein Therapeutics Market encompasses a range of
treatments and medicines used in the management of various chronic
disorders, including cancer, diabetes, autoimmune disorders, and
cardiovascular diseases. This market is driven by the development
of versatile therapies, such as Therapeutic protein drugs, which
utilize both genetically engineered proteins and natural proteins.
These proteins play a crucial role in modulating the activity of
specific molecules and sugars, thereby influencing the progression
of diseases.
The market for Protein Therapy is significant in major
healthcare institutions, where treatments like Chemotherapy and
Monoclonal antibodies segment are commonly administered for
immunological diseases and hematological disorders. The Protein
Therapy Market holds immense potential in Developing Economies,
where the demand for quality drugs and advanced treatments
continues to grow. Recombinant Proteins are a key segment of this
market, offering effective solutions for metabolic disorders
segment.
Market Research Overview
The Protein Therapeutics Market encompasses a range of
therapeutic products derived from proteins, including monoclonal
antibodies, enzymes, and peptides. These therapeutics offer unique
advantages, such as high specificity and efficacy, making them
valuable treatments for various diseases.
The market is driven by factors like increasing prevalence of
chronic diseases, technological advancements in protein production,
and growing demand for targeted therapies. Additionally, regulatory
approvals and collaborations between academic institutions and
biotech companies are further fueling market growth. Proteins are
used in various therapeutic areas, including oncology, neurology,
and immunology, among others. The market is expected to witness
significant growth in the coming years due to these factors.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Product
-
- MAbs
- Human Insulin
- Erythropoeitin
- Clotting Factors
- Others
- Application
-
- Metabolic Disorders
- Immunologic Disorders
- Hematological Disorders
- Cancer
- Genetic Disorders
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protein-therapeutics-market-size-is-set-to-grow-by-usd-172-8-billion-from-2024-2028--increased-demand-for-mabs-boost-the-market-technavio-302167918.html
SOURCE Technavio